Parkinson’s Disease: Psychosocial Impacts Rise as Disease Progresses

The early stages of Parkinson’s disease are often characterized by motor symptoms like tremor and rigidity, but a new study published in The Journal of Neurology reveals that the psychosocial impacts and non-motor symptoms—like fatigue, sleep disturbances, and cognitive changes—are equally, if not more, bothersome to patients. The findings underscore the need for a more holistic approach to care and clinical trial design, focusing on the patient experience beyond simply measuring motor function improvements.

Understanding the Patient Experience

Researchers followed 32 patients newly diagnosed with Parkinson’s disease for three years, collecting data through annual surveys and interviews. The study, a pre-competitive initiative led by the Critical Path Institute (C-Path), aimed to identify which symptoms and impacts mattered most to patients in the early stages of the disease. This function aligns with recommendations from the Food and Drug Administration (FDA) to evaluate therapies based on their ability to change the course of the disease, rather than just manage symptoms. Mammen JR, et al. J Neuro. 2026; doi:10.1007/s00415-026-13615-5.

“We are finally at the place in the development of new therapies for Parkinson’s disease where we are evaluating the ability of a therapy to change the course of the disease in early stages rather than just treating the symptoms after they’ve begun,” explained Cheryl Coon, PhD, vice president of the C-Path Clinical Outcome Assessment Program. Coon, who collaborated with the study authors, emphasized that many clinical trials prioritize symptom reduction in later stages, overlooking the importance of addressing early-stage concerns.

Symptoms and Impacts Over Time

At the three-year mark, 97% of patients reported difficulty communicating and altered self-concept. The most frequently reported bothersome motor symptoms included tremor (97%), gait difficulties (90%), balance issues (87%), fine motor problems (87%), slow movements (81%), and stiffness (71%). Interestingly, gait difficulties and balance issues became significantly more bothersome over the study period, increasing from 59.4% to 90.6% and 65.6% to 87.5% respectively (P < .01).

Beyond motor symptoms, fatigue, sleep problems, mood changes, and cognitive difficulties were consistently important to patients. While depression rates decreased from 41% at year one to 29% at year three, the study highlighted the increasing psychosocial impact of the disease. By year three, all patients reported that Parkinson’s affected their daily function, particularly in areas like fine motor skills, tremor, slow movements, cognitive function, stiffness, and gait/balance.

The effort required to perform daily activities also increased significantly, with all patients reporting greater exertion at year three compared to 36% at baseline (P < .001). 97% of patients reported difficulty communicating, 97% experienced altered self-concept, 84% felt embarrassment, 81% struggled with household activities, 81% were less able to participate in hobbies, and 69% faced limitations in driving—all representing substantial increases from the beginning of the study (P < .05).

The Role of Psychosocial Support and Coping Strategies

The study also revealed a growing sense of isolation among patients, with 16% reporting feeling isolated at year one increasing to 41% at year three (P < .05). Despite these challenges, all patients were actively engaging in strategies to cope with their symptoms, including exercise, meditation, stress management, and meaningful activities.

Notably, patients reported that cognitive and behavioral strategies for symptom control were often more effective than medication, with an average of six mentions per interview compared to three mentions for medication (P < .01). This suggests that empowering patients with coping mechanisms and self-management techniques can be highly beneficial. Psilocybin Improves Mood, Motor Symptoms in Patients With Parkinson’s Disease

Implications for Clinical Trials and Care

The findings have significant implications for how Parkinson’s disease is studied and treated. The researchers suggest that current patient-reported outcome measures may not adequately capture the progression of early disease during clinical trials, which typically run for 12 to 18 months. They advocate for incorporating digital monitoring technologies, such as wearable devices that track gait and balance, alongside traditional questionnaires to provide a more comprehensive assessment.

“When information that matters to patients is generated in clinical trials, it means that patients and clinicians will then have relevant information to have discussions about treatment options so that patients can choose the right option to gain them the care that meets their needs,” Coon said.

The study also highlights the importance of addressing the psychosocial needs of patients with early Parkinson’s disease. Providing access to support groups, counseling, and other resources can help patients cope with the emotional and social challenges of living with a chronic illness. The Parkinson’s Foundation offers a range of resources, including peer mentorship programs and educational materials, to support individuals and families affected by Parkinson’s. Parkinson’s Foundation

Looking Ahead: Refining Outcome Measures

The researchers emphasize the need to develop patient-centric endpoint measures for clinical trials, focusing on outcomes that are meaningful to individuals living with Parkinson’s disease. This includes incorporating digital data and capturing the lived experiences of patients to better understand the impact of the disease and the effectiveness of potential therapies.

Further research is needed to evaluate the long-term durability of interventions like Rock Steady Boxing, peer support groups, and meditation. The goal is to develop and approve therapies that not only alleviate symptoms but also prevent or slow the progression of the disease, improving the quality of life for those affected by Parkinson’s.

For more information:

Cheryl Coon, PhD can be reached at [email protected].